Mometahexal Heuschnupfenspray (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nose. This interaction suppresses the production of inflammatory cytokines and mediators, decreasing swelling, mucus formation and vascular leakage, which together reduce the classic symptoms of nasal allergy.

The exact dosing regimen is set by the prescribing healthcare professional. In typical practice, one spray into each nostril once daily is common for adults, but the prescriber may adjust the frequency or amount based on individual response and age.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both mometasone and fluticasone are intranasal glucocorticoids with high receptor affinity and once‑daily dosing options. Mometasone has a slightly higher potency per microgram and a low systemic bioavailability, which may translate into a marginally lower risk of systemic effects, though clinical outcomes are generally comparable.

Store the spray at room temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

Before the first use, prime the pump by spraying a few times into the air. Tilt the head slightly forward, insert the tip into one nostril, close the opposite nostril with a finger, and gently press the actuator while breathing in through the nose. Repeat in the other nostril if prescribed.

Serious but rare risks include nasal septal perforation, severe or recurrent nosebleeds, opportunistic fungal infections of the nasal passages, and systemic glucocorticoid effects such as adrenal suppression, especially with prolonged high‑dose use. Patients should report any unusual nasal bleeding or visual changes promptly.

Individuals with a known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients who have had recent nasal surgery or trauma, and it is not recommended for children younger than two years unless specifically directed by a physician.